Part I: new frontiers in antibacterial drug discovery

Keywords: antibacterial • antibiotic • drug discovery

That the success of modern medical practice, and the improved levels of health in society more generally, has resulted from the chance discovery of penicillin nearly a century ago, is widely acknowledged, but perhaps more problematic has been the slow but now increasing realization that the benefit from small-molecule antibiotics may prove to be short-lived [1]. Reports from the international arena are now appearing which suggest that urgent action is required to identify next-generation systems, and this requires attention not only to scientific, but also intellectual property, commercial and marketing considerations, along with changes in societal expectations [2–4]. The task at hand is significant, urgent and expensive, but comes at a time when there are many other competing demands on international resources, in areas ranging from energy to water to security [5]. For this reason, a global approach is needed [6], but in the race to solve these issues, paradoxically, the most appropriate way forward is not necessarily so clear, and the need for progress in fundamental science is all too easily overlooked. This two-part issue, ‘New Frontiers in Antibacterial Drug Discovery’, includes some of the most recent developments in antibacterial science, with perspectives from key players across a spectrum of activity. K Bush addresses the issue of resistance in Gram-negative bacteria [7],

and novel targets for antibacterial drug discovery, including mediation of CsrA–RNA interaction [8], cyclic nucleotide-regulated biofilm formation [9], New Delhi Metallo- β -lactamase [10], and cell-wall metabolism in *Pseudomonas aeruginosa* [11], are all discussed. Novel small molecules, including polyamines [12], as new antibacterials are also highlighted. Finally, M Cooper and colleagues from Community for Open Antimicrobial Drug Discovery (CO-ADD) in Brisbane outline their approach to providing freely available high-quality compound screening to the global chemical community, in the search for new active small molecules [13].

The opportunities in and potential for antibacterial research are considerable, and I am very thankful to the authors for their contributions in this special issue. I hope that it will widely stimulate interest in, and the creation of novel ideas for, the urgent work that is required.

Financial & competing interests disclosure

MG Moloney is a Professor of Chemistry at the University of Oxford. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

- 1 Baker S. A return to the pre-antimicrobial era? *Science* 347(6226), 1064–1066 (2015).
- 2 Gelband H, Miller-Petrie M, Pant S Center for Disease Dynamics, Economics & Policy *et al.* *State of the World's Antibiotics, 2015*. Washington, DC, USA (2015).

Mark G Moloney

Chemistry Research Laboratory,
University of Oxford, 12 Mansfield Road,
Oxford, OX1 3TA, UK
mark.moloney@chem.ox.ac.uk

- 3 World Health Organization. Antimicrobial resistance (2014). www.who.int/mediacentre/factsheets/
- 4 O'Neill. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. (2014). <http://amr-review.org/sites/>
- 5 Wise R, Piddock LJV. *The Urgent Need Regenerating Antibacterial Drug Discovery Development*. British Society for Antimicrobial Chemotherapy (2010).
- 6 Laxminarayan R, Duse A, Wattal C *et al.* Antibiotic resistance – the need for global solutions. *Lancet* 13, 1057–1098 (2014).
- 7 Bush K. Overcoming β -lactam resistance in Gram-negative pathogens. *Future Med. Chem.* 8(9), 921–924 (2016).
- 8 Maurer CK, Fruth M, Empting M *et al.* Discovery of the first small-molecule CsrA–RNA interaction inhibitors using biophysical screening technologies. *Future Med. Chem.* 8(9), 931–947 (2016).
- 9 Short FL, Rugjee KN, An S, Ryan RP. Combating chronic bacterial infections by manipulating cyclic nucleotide-regulated biofilm formation. *Future Med. Chem.* 8(9), 949–961 (2016).
- 10 Groundwater PW, Xu S, Lai F *et al.* New Delhi Metallo- β -lactamase (NDM-1): structure, inhibitors, and detection of producers. *Future Med. Chem.* 8(9), 993–1012 (2016).
- 11 Lamers RP, Burrows LL. *Pseudomonas aeruginosa*: targeting cell-wall metabolism for new antibacterial discovery and development. *Future Med. Chem.* 8(9), 975–992 (2016).
- 12 Blanchet M, Borselli D, Brunel JM. Polyamine derivatives: a revival of an old neglected scaffold to fight resistant Gram-negative bacteria? *Future Med. Chem.* 8(9), 963–973 (2016).
- 13 Hansford KA, Blaskovich MAT, Cooper MA. Chemical philanthropy: a path forward for antibiotic discovery? *Future Med. Chem.* 8(9), 925–929 (2016).